indication

Anxiety

Competitive landscape projected to multisensory stimulation therapy’s launch window

as of 2026-07-01
Competitive set
2
2 approved · 0 pipeline

Projection timeline

actual past → guided future · protection walls overlaid
18 events
2020
2022
2024
2026
2028
2030
2032
2034
today
multisensory stimulation therapy launch window
guided / estimated ↑
actual ↓
focal / guidedapprovallabel expansiontrial readoutcongressnclustered events (click to expand)guided (dashed = directional)competitor patent cliff

Competitive set

resolved drugs with trials in this indication
drugUnknown
Quetiapine
US-approved 1997 · SEROQUEL XR
Phase 31 trial
OwnerAstraZeneca
Protection—
drugCompleted
Brexpiprazole (Rexulti)
US-approved 2015 · Rexulti
Phase 31 trial
OwnerOtsuka Pharmaceutical Development & Commercialization, Inc.
Protection2033

Market size

prevalence as a range, not a number